Basic Research in Cardiology最新文献

The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity. 表观遗传学在抗癌药物诱导的心脏毒性中的作用和机制。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-05-09 DOI: 10.1007/s00395-024-01054-0

Xuening Liu, Zijian Li

引用次数: 0

Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. 免疫检查点抑制剂心血管毒性的分子指纹。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-07-17 DOI: 10.1007/s00395-024-01068-8

Tamás G Gergely, Zsófia D Drobni, Nabil V Sayour, Péter Ferdinandy, Zoltán V Varga

{"title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors.","authors":"Tamás G Gergely, Zsófia D Drobni, Nabil V Sayour, Péter Ferdinandy, Zoltán V Varga","doi":"10.1007/s00395-024-01068-8","DOIUrl":"10.1007/s00395-024-01068-8","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of the immune system against malignant cells. However, their use is associated with a spectrum of adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to cardiovascular toxicity associated with ICIs. First, the dysregulation of immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand (PD-L1), and molecular mimicry with cardiac autoantigens, leads to immune-related adverse events, including myocarditis and vasculitis. These events result from the aberrant activation of T cells against self-antigens within the myocardium or vascular endothelium. Second, the disruption of immune homeostasis by ICIs can lead to autoimmune-mediated inflammation of cardiac tissues, manifesting as cardiac dysfunction and heart failure, arrhythmias, or pericarditis. Furthermore, the upregulation of inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, and interleukin-17 contributes to cardiac and endothelial dysfunction, plaque destabilization, and thrombosis, exacerbating cardiovascular risk on the long term. Understanding the intricate mechanisms of cardiovascular side effects induced by ICIs is crucial for optimizing patient care and to ensure the safe and effective integration of immunotherapy into a broader range of cancer treatment protocols. The clinical implications of these mechanisms underscore the importance of vigilant monitoring and early detection of cardiovascular toxicity in patients receiving ICIs. Future use of these key pathological mediators as biomarkers may aid in prompt diagnosis of cardiotoxicity and will allow timely interventions.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"187-205"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights. 运动、癌症和心血管系统：临床效果和机理认识。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-02-14 DOI: 10.1007/s00395-024-01034-4

Simon Wernhart, Tienush Rassaf

引用次数: 0

Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. 钠-葡萄糖共转运体 2 抑制剂与癌症患者：从糖尿病到心脏保护及其他。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-06-27 DOI: 10.1007/s00395-024-01059-9

Massimiliano Camilli, Marcello Viscovo, Luca Maggio, Alice Bonanni, Ilaria Torre, Claudio Pellegrino, Priscilla Lamendola, Lorenzo Tinti, Luciana Teofili, Stefan Hohaus, Gaetano Antonio Lanza, Peter Ferdinandy, Zoltan Varga, Filippo Crea, Antonella Lombardo, Giorgio Minotti

{"title":"Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.","authors":"Massimiliano Camilli, Marcello Viscovo, Luca Maggio, Alice Bonanni, Ilaria Torre, Claudio Pellegrino, Priscilla Lamendola, Lorenzo Tinti, Luciana Teofili, Stefan Hohaus, Gaetano Antonio Lanza, Peter Ferdinandy, Zoltan Varga, Filippo Crea, Antonella Lombardo, Giorgio Minotti","doi":"10.1007/s00395-024-01059-9","DOIUrl":"10.1007/s00395-024-01059-9","url":null,"abstract":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascular risk and/or candidate to receive cardiotoxic therapies. This review will cover biological foundations and clinical evidence for SGLT2i modulating myocardial function and metabolism, with a focus on their possible use as cardioprotective agents in the cardio-oncology settings. Furthermore, we will explore recently emerged SGLT2i effects on hematopoiesis and immune system, carrying the potential of attenuating tumor growth and chemotherapy-induced cytopenias.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"241-262"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardioprotection of voluntary exercise against breast cancer-induced cardiac injury via STAT3. 自愿运动通过 STAT3 对乳腺癌诱发的心脏损伤起到保护作用

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-08-19 DOI: 10.1007/s00395-024-01076-8

Lan Wu, Zhi-Zheng Li, Hao Yang, Li-Zhi Cao, Xiao-Ying Wang, Dong-Liang Wang, Emeli Chatterjee, Yan-Fei Li, Gang Huang

{"title":"Cardioprotection of voluntary exercise against breast cancer-induced cardiac injury via STAT3.","authors":"Lan Wu, Zhi-Zheng Li, Hao Yang, Li-Zhi Cao, Xiao-Ying Wang, Dong-Liang Wang, Emeli Chatterjee, Yan-Fei Li, Gang Huang","doi":"10.1007/s00395-024-01076-8","DOIUrl":"10.1007/s00395-024-01076-8","url":null,"abstract":"Exercise is an effective way to alleviate breast cancer-induced cardiac injury to a certain extent. However, whether voluntary exercise (VE) activates cardiac signal transducer and activator of transcription 3 (STAT3) and the underlying mechanisms remain unclear. This study investigated the role of STAT3-microRNA(miRNA)-targeted protein axis in VE against breast cancer-induced cardiac injury.VE for 4 weeks not only improved cardiac function of transgenic breast cancer female mice [mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT +)] compared with littermate mice with no cancer (MMTV-PyMT -), but also increased myocardial STAT3 tyrosine 705 phosphorylation. Significantly more obvious cardiac fibrosis, smaller cardiomyocyte size, lower cell viability, and higher serum tumor necrosis factor (TNF)-α were shown in MMTV-PyMT + mice compared with MMTV-PyMT - mice, which were ameliorated by VE. However, VE did not influence the tumor growth. MiRNA sequencing identified that miR-181a-5p was upregulated and miR-130b-3p was downregulated in VE induced-cardioprotection. Myocardial injection of Adeno-associated virus serotype 9 driving STAT3 tyrosine 705 mutations abolished cardioprotective effects above. Myocardial STAT3 was identified as the transcription factor binding the promoters of pri-miR-181a (the precursor of miR-181a-5p) and HOX transcript antisense RNA (HOTAIR, sponged miR-130b-3p) in isolated cardiomyocytes. Furthermore, miR-181a-5p targeting PTEN and miR-130b-3p targeting Zinc finger and BTB domain containing protein 20 (Zbtb20) were proved in AC-16 cells. These findings indicated that VE protects against breast cancer-induced cardiac injury via activating STAT3 to promote miR-181a-5p targeting PTEN and to promote HOTAIR to sponge miR-130b-3p targeting Zbtb20, helping to develop new targets in exercise therapy for breast cancer-induced cardiac injury.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"113-131"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. 免疫检查点抑制剂疗法心脏毒性的临床前模型。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-07-22 DOI: 10.1007/s00395-024-01070-0

Florian Buehning, Tobias Lerchner, Julia Vogel, Ulrike B Hendgen-Cotta, Matthias Totzeck, Tienush Rassaf, Lars Michel

{"title":"Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy.","authors":"Florian Buehning, Tobias Lerchner, Julia Vogel, Ulrike B Hendgen-Cotta, Matthias Totzeck, Tienush Rassaf, Lars Michel","doi":"10.1007/s00395-024-01070-0","DOIUrl":"10.1007/s00395-024-01070-0","url":null,"abstract":"Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer treatment, harnessing the immune system to combat malignancies by targeting checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). The use of ICI therapy generates distinctive immune-related adverse events (irAEs) including cardiovascular toxicity, necessitating targeted research efforts. This comprehensive review explores preclinical models dedicated to ICI-mediated cardiovascular complications including myocarditis. Tailored preclinical models of ICI-mediated myocardial toxicities highlight the key role of CD8+ T cells, emphasizing the profound impact of immune checkpoints on maintaining cardiac integrity. Cytokines and macrophages were identified as possible driving factors in disease progression, and at the same time, initial data on possible cardiac antigens responsible are emerging. The implications of contributing factors including thoracic radiation, autoimmune disorder, and the presence of cancer itself are increasingly understood. Besides myocarditis, mouse models unveiled an accelerated progression of atherosclerosis, adding another layer for a thorough understanding of the diverse processes involving cardiovascular immune checkpoint signalling. This review aims to discuss current preclinical models of ICI cardiotoxicity and their potential for improving enhanced risk assessment and diagnostics, offering potential targets for innovative cardioprotective strategies. Lessons from ICI therapy can drive novel approaches in cardiovascular research, extending insights to areas such as myocardial infarction and heart failure.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"171-185"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging cardiology and oncology in the era of precision medicine.

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2025-02-03 DOI: 10.1007/s00395-025-01097-x

Tienush Rassaf

引用次数: 0

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-09-03 DOI: 10.1007/s00395-024-01077-7

Giuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, Luciano Mutti, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Demetrio Labate, Sebastiano Macheda, Nicole Carabetta, Youssef S Abdelwahed, Ulf Landmesser, Pierfrancesco Tassone, Pierosandro Tagliaferri, Salvatore De Rosa, Daniele Torella

{"title":"Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients.","authors":"Giuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, Luciano Mutti, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Demetrio Labate, Sebastiano Macheda, Nicole Carabetta, Youssef S Abdelwahed, Ulf Landmesser, Pierfrancesco Tassone, Pierosandro Tagliaferri, Salvatore De Rosa, Daniele Torella","doi":"10.1007/s00395-024-01077-7","DOIUrl":"10.1007/s00395-024-01077-7","url":null,"abstract":"Immunotherapy represents an emergent and heterogeneous group of anticancer treatments harnessing the human immune-surveillance system, including immune-checkpoint inhibitor monoclonal antibodies (mAbs), Chimeric Antigen Receptor T Cells (CAR-T) therapy, cancer vaccines and lymphocyte activation gene-3 (LAG-3) therapy. While remarkably effective against several malignancies, these therapies, often in combination with other cancer treatments, have showed unforeseen toxicity, including cardiovascular complications. The occurrence of immuno-mediated adverse (irAEs) events has been progressively reported in the last 10 years. These irAEs present an extended range of severity, from self-limiting to life-threatening conditions. Although recent guidelines in CardioOncology have provided important evidence in managing cancer treatments, they often encompass general approaches. However, a specific focus is required due to the particular etiology, unique risk factors, and associated side effects of immunotherapy. This review aims to deepen the understanding of the prevalence and nature of cardiovascular issues in patients undergoing immunotherapy, offering insights into strategies for risk stratification and management.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"153-169"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardioprotection strategies for anthracycline cardiotoxicity. 蒽环类药物心脏毒性的心脏保护策略。

IF 7.5 1区医学

Basic Research in Cardiology Pub Date : 2025-02-01 Epub Date: 2024-09-09 DOI: 10.1007/s00395-024-01078-6

Andrea Moreno-Arciniegas, Laura Cádiz, Carlos Galán-Arriola, Agustín Clemente-Moragón, Borja Ibáñez

{"title":"Cardioprotection strategies for anthracycline cardiotoxicity.","authors":"Andrea Moreno-Arciniegas, Laura Cádiz, Carlos Galán-Arriola, Agustín Clemente-Moragón, Borja Ibáñez","doi":"10.1007/s00395-024-01078-6","DOIUrl":"10.1007/s00395-024-01078-6","url":null,"abstract":"Thanks to the fantastic progress in cancer therapy options, there is a growing population of cancer survivors. This success has resulted in a need to focus much effort into improving the quality of life of this population. Cancer and cardiovascular disease share many common risk factors and have an interplay between them, with one condition mechanistically affecting the other and vice versa. Furthermore, widely prescribed cancer therapies have known toxic effects in the cardiovascular system. Anthracyclines are the paradigm of efficacious cancer therapy widely prescribed with a strong cardiotoxic potential. While some cancer therapies cardiovascular toxicities are transient, others are irreversible. There is a growing need to develop cardioprotective therapies that, when used in conjunction with cancer therapies, can prevent cardiovascular toxicity and thus improve long-term quality of life in survivors. The field has three main challenges: (i) identification of the ultimate mechanisms leading to cardiotoxicity to (ii) identify specific therapeutic targets, and (iii) more sensible diagnostic tools to early identify these conditions. In this review we will focus on the cardioprotective strategies tested and under investigation. We will focus this article into anthracycline cardiotoxicity since it is still the agent most widely prescribed, the one with higher toxic effects on the heart, and the most widely studied.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":" ","pages":"71-90"},"PeriodicalIF":7.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravenous and oral administration of the synthetic RNA drug, TY1, reverses heart failure with preserved ejection fraction in mice 静脉注射和口服合成 RNA 药物 TY1 可逆转小鼠射血分数保留型心力衰竭

IF 9.5 1区医学

Basic Research in Cardiology Pub Date : 2024-12-31 DOI: 10.1007/s00395-024-01095-5

Kazutaka Miyamoto, Xaviar M. Jones, Shukuro Yamaguchi, Alessandra Ciullo, Chang Li, Joshua Godoy Coto, Kara Tsi, Jessica Anderson, Ashley Morris, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim

{"title":"Intravenous and oral administration of the synthetic RNA drug, TY1, reverses heart failure with preserved ejection fraction in mice","authors":"Kazutaka Miyamoto, Xaviar M. Jones, Shukuro Yamaguchi, Alessandra Ciullo, Chang Li, Joshua Godoy Coto, Kara Tsi, Jessica Anderson, Ashley Morris, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim","doi":"10.1007/s00395-024-01095-5","DOIUrl":"https://doi.org/10.1007/s00395-024-01095-5","url":null,"abstract":"TY1, a synthetic non-coding RNA (ncRNA) bioinspired by small Y RNAs abundant in extracellular vesicles (EVs), decreases cGAS/STING activation in myocardial infarction and thereby attenuates inflammation. Motivated by the concept that heart failure with preserved ejection fraction (HFpEF) is a systemic inflammatory disease, we tested TY1 in a murine model of HFpEF. Intravenous TY1, packaged in a transfection reagent, reversed the cardiac and systemic manifestations of HFpEF in two-hit obese-hypertensive mice, without inducing weight loss. The effects of TY1 were specific, insofar as they were not reproduced by a control RNA of the same nucleotide content but in scrambled order. TY1 consistently suppressed myocardial stress-induced MAP kinase signaling, as well as downstream inflammatory, fibrotic, and hypertrophic gene pathways in heart tissue. TY1 not only prevented but actually reversed key pathological processes underlying HFpEF, with no evidence of toxicity. Most noteworthy from a practical perspective, the effects of intravenous TY1 were reproduced by feeding HFpEF mice an oral micellar formulation of TY1. As the prototype for a novel class of ncRNA drugs which target cell stress, TY1 exhibits exceptional disease-modifying bioactivity in HFpEF.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"1 1","pages":""},"PeriodicalIF":9.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142905107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0